Work

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-158998

Authors: Neha Bhagwat, Bruce Ruggeri, Yang Zhang, Yaron Mosesson, Clare Killick-Cole, Veena Jagannathan, Peggy Scherle

Institution: Prelude Therapeutics Incorporated (United States)

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310159189

FWCI: 1.104

Cites:

Cited by: 5

Related to: 10